Previous Article | Next Article 
Clinical and Diagnostic Laboratory Immunology, March 1998, p. 225-229, Vol. 5, No. 2
1071-412X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Lipopolysaccharide from Nonvirulent
Ara+ Burkholderia pseudomallei Isolates Is
Immunologically Indistinguishable from Lipopolysaccharide from Virulent
Ara
Clinical Isolates
Narisara
Anuntagool,1
Pakamas
Intachote,1
Vanaporn
Wuthiekanun,2
Nicholas J.
White,2,3 and
Stitaya
Sirisinha1,4,*
Laboratory of Immunology, Chulabhorn Research
Institute,1
Department of Microbiology,
Faculty of Science,4 and
Faculty of
Tropical Medicine,2 Mahidol University, Bangkok,
Thailand, and
Nuffield Department of Clinical Medicine,
University of Oxford, Oxford, United Kingdom3
Received 14 July 1997/Returned for modification 21 October
1997/Accepted 15 December 1997
 |
ABSTRACT |
Different lines of evidence suggest that a discrepancy between the
distribution of Burkholderia (Pseudomonas) pseudomallei in
the environment and the distribution of the disease melioidosis is
attributable, at least in part, to phenotypic differences between clinical and some environmental isolates. Two antigenically and biochemically distinct biotypes have been described, only one of which
is virulent. In this study, lipopolysaccharides (LPSs) were extracted
by the proteinase K digestion method from a total of 214 B. pseudomallei isolates, and their immunoreactivities with sera
from patients with different clinical spectra and with other infections
were evaluated. With the exception of 4 isolates from a total of 214 tested, the sodium dodecyl sulfate-polyacrylamide gel electrophoresis
silver-staining profiles of the LPSs from the two biotypes showed
identical ladder patterns that were typical for smooth LPSs from other
gram-negative bacteria. The 210 isolates with typical LPS patterns (119 Ara
clinical, 13 Ara
soil, 70 Ara+ soil, and 8 reference National Type Culture Collection
strains) also exhibited similar immunoblot profiles against pooled sera from patients with melioidosis and hyperimmune mouse sera. Concordant findings were noted in the indirect enzyme-linked immunosorbent assay
with Ara
and Ara+ LPSs to coat the microtiter
plates. The LPSs of the different B. pseudomallei biotypes
appear antigenically indistinguishable. It is, therefore, unlikely that
this component is related to the virulence and pathogenicity of
B. pseudomallei.
 |
INTRODUCTION |
Burkholderia (Pseudomonas)
pseudomallei is the causative agent of melioidosis, a potentially
fatal human infection in the tropics (3, 4, 28). The disease
has diverse clinical manifestations, from localized infection to acute
fatal septicemia. Subclinical infections, which are defined by the
detection of hemagglutinating antibody in people residing in areas of
endemicity, e.g., northeastern Thailand and northern Australia, are
very common. Antibody to lipopolysaccharide (LPS) is believed to be a
major contributor to seropositivity, since the indirect
hemagglutination assay routinely used for screening in a diagnostic
laboratory (28) is biased toward the detection of anti-LPS.
In Thailand, melioidosis is largely restricted to the northeast, yet
B. pseudomallei has been recovered from the environment,
e.g., from soil throughout the country (23, 27). Clinical
isolates from different geographical locations, from Thailand and
Malaysia to Australia, appeared to have similar morphological and
biochemical characteristics (28). Although B. pseudomallei has been reported to possess two structurally different forms of LPS (16), a previous study by Pitt et al. (18) showed the LPSs from a limited number of clinical
isolates, presumably belonging to the Ara
biotype
described in the present communication, to be rather homogeneous with
regard to their immunoreactivities with human and animal sera.
It was shown subsequently (27) that all clinical B. pseudomallei isolates failed to utilize L-arabinose
(Ara
), whereas some soil isolates from the areas of
endemic infection could utilize this carbohydrate (Ara+).
It has been demonstrated very recently that the Ara
biotype is virulent in experimental animals (1, 22).
Differences in the virulence of B. pseudomallei could result
from differences in the LPS molecules, which are a known toxic
component of various gram-negative organisms. However, the results
presented in this study showed that the LPSs from Ara
and
Ara+ biotypes were indistinguishable from one another with
regard to sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) profiles and immunoreactivities with immune sera.
 |
MATERIALS AND METHODS |
Bacterial isolates.
A total of 123 clinical B. pseudomallei isolates (Ara
) were from patients
admitted to University Hospital (Khon Kaen University) in Khon Kaen
province and Sappasitprasong Hospital in Ubon Ratchatani province in
the northeastern part of Thailand, where infection is endemic. Thirteen
Ara
soil isolates and 70 Ara+ soil isolates
used were collected from different geographical locations (Table
1). All isolates were originally
identified as B. pseudomallei based on their biochemical
characteristics, colonial morphologies on selective media, antibiotic
sensitivity profiles, and reactions with polyclonal antibody (27,
28). They were classified subsequently into Ara+ or
Ara
biotypes based on their abilities to utilize
L-arabinose (27). In addition to these 206 local
isolates, eight reference B. pseudomallei strains (NTCC
1688, NTCC 4845, NTCC 4846, NTCC 6700, NTCC 7131, NTCC 7383, NTCC 8016, and NTCC 8707) were also included in the analysis.
Serum specimens.
The sera from patients with culture-proven
melioidosis and other septicemias caused by gram-negative organisms
used in this study (Table 2) were the
same as those described in the previous report (21). Normal
sera were collected from healthy individuals in areas of endemicity and
nonendemicity. Positive and negative reference sera used throughout
this study were pooled from four to five specimens from each group,
aliquoted, and kept frozen at
20°C.
Production of mouse anti-LPS antibody.
Six-week-old female
BALB/c mice were immunized intraperitoneally with the Ara
LPS prepared by the phenol-chloroform-petroleum ether method (10). Each animal received an initial injection of 100 µg
of LPS in complete Freund's adjuvant followed 1 month later by another injection of the same amount of LPS in incomplete Freund's adjuvant. The animals were bled 3 weeks later, and the antibody titer of pooled
serum tested by indirect enzyme-linked immunosorbent assay (ELISA)
against purified LPS was higher than 1:200,000.
Preparation of B. pseudomallei LPS.
LPS was
extracted from individual B. pseudomallei isolates by either
the proteinase K (15) or the phenol-chloroform-petroleum ether (10) method. The two preparations were similar to each other with regard to SDS-PAGE profiles and immunoreactivities with
immune sera (unpublished data). Unless otherwise specified, the data
presented in this study were obtained with the proteinase K product
because of its simplicity and higher yield. Briefly, clinical and soil
isolates of both biotypes were grown individually on trypticase agar at
37°C for 48 h and washed with phosphate-buffered saline at pH
7.2, and then the bacterial suspensions were adjusted to contain
approximately 109 CFU/ml, based on turbidimetric
measurement. After centrifugation at 5,000 × g for 15 min, the supernatant fluid was discarded, the pellet was resuspended in
an equal volume of 4% mercaptoethanol in 6 M urea, and the suspension
was boiled for 20 min. Then, 1/10 volume of proteinase K (2.5 mg/ml)
was added and digestion was allowed to proceed at 50°C for 16 h.
The enzymatic reaction was terminated by adding protease inhibitor
(phenylmethylsulfonyl fluoride) at a final concentration of 20 µg/ml.
The digest was then dialyzed for 2 days against several changes of
distilled water and centrifuged at 5,000 × g for 30 min to remove bacterial debris. The LPS solution was lyophilized, and
its carbohydrate content was determined by the orcinol-sulfuric acid
method (26). The LPS prepared as described was used in
indirect ELISA. The LPS to be used for SDS-PAGE and immunoblot
experiments was extracted in a similar manner, with the exception that
proteinase K digestion was carried out in the presence of 2% SDS-4%
mercaptoethanol-10% glycerol in 1 M Tris buffer (pH 6.8) instead of 6 M urea.
SDS-PAGE and immunoblots.
SDS-PAGE was performed according
to the method described by Laemmli (12) as described in
detail in our previous report (21). Each lane of the 12%
gel was loaded with 10 µg of LPS, and after electrophoresis was
terminated, the separated components were detected with a modified
silver stain (5). For the immunoblots, the electrophoresed
components were electrotransferred immediately onto a nitrocellulose
membrane (19) and then probed with a reference positive
human serum or immune mouse serum. The optimal serum dilutions were
1:7,000 for human serum and 1:500 for mouse serum. The reactions were
detected with horseradish peroxidase-conjugated rabbit anti-human
immunoglobulin G (IgG) or anti-mouse immunoglobulin (Dako A/S,
Copenhagen, Denmark), respectively. Pooled sera from healthy
individuals resident in areas of nonendemicity and preimmunized mouse
sera, respectively, were used as negative controls. Molecular weights
were calculated as described by Weber and Osborn (25).
ELISA.
Indirect ELISA was performed to compare the
immunoreactivities of Ara
and Ara+ LPSs with
sera from different groups of individuals as originally described for
the detection of IgG antibody to affinity-purified antigen
(21). The LPS preparations for coating the microtiter plates
were both used at a concentration of 2.5 µg/ml. Affinity-purified antigen prepared as described in our previous report (21),
which was used at a concentration of 0.7 µg/ml, was included for
comparison. All sera were used at an optimal dilution of 1:2,000, and
reactions were detected with horseradish peroxidase-conjugated rabbit
anti-human IgG.
Other techniques.
Protein concentrations were determined as
described by Lowry et al., with bovine serum albumin as the standard
(13). Quantitation of LPS was based on its carbohydrate
content, which was measured by an orcinol-sulfuric acid method
(26).
 |
RESULTS |
SDS-PAGE profile of LPSs extracted from Ara
and
Ara+ B. pseudomallei isolates.
The
proteinase K-extracted LPSs from both Ara
and
Ara+ soil isolates and Ara
clinical isolates
were subjected to SDS-PAGE, and their silver-staining profiles were
compared. Representative patterns from the three groups are shown in
Fig. 1. With the exception of four
clinical isolates, the remaining 210 isolates (140 Ara
and 70 Ara+ isolates) exhibited identical staining
profiles, showing the distinctive ladder pattern typical for LPSs from
other gram-negative bacteria. The results typically showed at least 20 to 30 repeating bands with uniform spacing, which was particularly
obvious in the region between 29 and 43 kDa. The atypical LPS pattern
exhibited by two of the four clinical isolates is shown in Fig.
2. However, a densely stained
high-molecular-mass region (68- to 97-kDa position) was present in all
extracts. In this region, the staining could not be resolved into a
distinct ladder as in the lower region (Fig. 1 and 2). The
silver-staining profiles of clinical and soil isolates from Thailand
and Vietnam were identical and were similar to those exhibited by the
eight reference strains (data not shown).

View larger version (118K):
[in this window]
[in a new window]
|
FIG. 1.
Representative typical silver-stained SDS-PAGE profiles
of LPSs extracted from 214 Ara and Ara+
B. pseudomallei isolates. Lanes: 1 and 2, Ara
clinical isolates; 3 and 4, Ara soil isolates; 5 to 8, Ara+ soil isolates. Numbers on the left are molecular
weight markers (in thousands).
|
|

View larger version (72K):
[in this window]
[in a new window]
|
FIG. 2.
Atypical silver-stained SDS-PAGE profiles of LPSs
extracted from two clinical Ara isolates (lanes 2 and 3).
A representative pattern of typical B. pseudomallei isolates
is shown for comparison (lane 1). Numbers on the left are molecular
weight markers (in thousands).
|
|
Immunoblot profiles of different LPS extracts with anti-B.
pseudomallei sera.
Representative profiles from the three
groups of B. pseudomallei, namely, Ara
clinical, Ara
soil, and Ara+ soil, are shown
in Fig. 3 and
4. When the isolates were probed with
human melioidosis serum (Fig. 3), the immunoreactive patterns of all
isolates from the three groups were indistinguishable from one another.
The characteristic LPS ladders could be readily observed. In addition
to these ladders, all extracts exhibited patterns of unresolved
immunoreactive banding in the 68- to 97-kDa region similar to the ones
noted with the silver staining shown in Fig. 2. However, unlike the
results with silver staining, with the immunoblots another dense
unresolved, immunoreactive component at the 97- to 200-kDa position
could also be detected in all LPS extracts. Essentially identical
immunoblot patterns were observed when the reactions were developed
with mouse anti-LPS serum (Fig. 4). Rabbit antisera to Ara+
or Ara
whole-cell antigens reacted equally well with the
LPS from either biotype in the ELISA and the immunoblotting assay (data
not shown).

View larger version (111K):
[in this window]
[in a new window]
|
FIG. 3.
Representative immunoblot profiles of LPSs from
Ara and Ara+ B. pseudomallei
isolates against sera pooled from patients with culture-proven
melioidosis. The serum was used at a 1:7,000 dilution. Lanes: 1 and
2, Ara clinical isolates; 3 and 4, Ara soil
isolates; 5 to 8, Ara+ soil isolates. Numbers on the left
are molecular weight markers (in thousands).
|
|

View larger version (100K):
[in this window]
[in a new window]
|
FIG. 4.
Representative immunoblot profiles of LPSs from
Ara and Ara+ B. pseudomallei
isolates against immune mouse serum. The serum was used at a dilution
of 1:500. Lanes: 1 and 2, Ara clinical isolates; 3 and 4, Ara soil isolates; 5 to 8, Ara+ soil
isolates. Numbers on the left are molecular weight markers (in
thousands).
|
|
Immunoreactivities of Ara
and Ara+ LPSs
with different groups of human sera.
To analyze the anti-LPS
responses in melioidosis patients with different clinical spectra and
possible immunological cross-reactivities with sera from patients with
other infections, both the immunoblot assays (Fig.
5 and 6)
and the indirect ELISA (Table 2) for IgG antibody were employed. To
avoid bias results possibly arising from individual strain variation,
at least four respective individual LPS preparations from either the
Ara
or the Ara+ biotype were pooled and used
in the experiment. Representative immunoreactive profiles shown in Fig.
5 and 6 are consistent with those presented earlier (Fig. 3),
demonstrating typical LPS ladder appearance. Sera from patients with
septicemia (Fig. 5 and 6, lanes 1 to 3) and localized infections (lanes
4 to 6) exhibited similar anti-LPS patterns, regardless of the type of
LPS used in the analyses. Under the same conditions, almost all sera
from patients with other infections (lanes 7 to 9) and healthy
individuals (lanes 10 to 15) failed to give positive immunoblots.
However, a few serum specimens from these individuals reacted weakly,
particularly when the experiment was performed with LPS extracted from
the Ara+ B. pseudomallei biotype.

View larger version (90K):
[in this window]
[in a new window]
|
FIG. 5.
Immunoreactivities of LPSs from the Ara+
biotype. Sera were from patients with septicemic melioidosis (lanes 1 to 3), melioidosis patients with localized infections (lanes 4 to 6),
and patients with other infections caused by gram-negative organisms
(lanes 7 to 9) and from normal individuals from areas where infection
is endemic (lanes 10 to 12) and nonendemic (lanes 13 to 15). All sera
were used at a 1:7,000 dilution. Numbers on the left are molecular
weight markers (in thousands).
|
|

View larger version (86K):
[in this window]
[in a new window]
|
FIG. 6.
Immunoreactivities of pooled LPS extracted from
Ara B. pseudomallei. See legend to
Fig. 5 for details.
|
|
The LPS preparations from both biotypes coating the microtiter plates
reacted equally well in the indirect ELISA with sera from melioidosis
patients with and without septicemia (Table 2). The ELISA data with
these two LPS preparations resembled those of the affinity-purified
antigen simultaneously analyzed and shown in Table 2 for comparison
(r = 0.689). In terms of specificity and potential
diagnostic value, either one of these LPS preparations compared
favorably with or was slightly better than the affinity-purified antigen reported earlier (21).
 |
DISCUSSION |
The results presented in this study show that the LPSs from the
Ara
clinical and Ara
soil isolates were
indistinguishable and were also identical to those of the
Ara+ soil isolates with regard to SDS-PAGE profiles (Fig.
1) and immunoreactivities with the melioidosis sera (Fig. 3 and 4).
With the exception of 4 isolates, the 210 remaining isolates,
regardless of biotype or source of origin, gave similar proteinase
K-digested SDS-PAGE profiles, showing characteristic ladder patterns
with identical spacings and positions of bands. The observation
presented in our study is consistent with the earlier report of Pitt et
al., which demonstrated that 12 clinical strains of B. pseudomallei, presumably of the Ara
biotype, from
Southeast Asia and Australia isolated over a period of 70 years
exhibited identical LPS moieties (18). The antigenic similarity between the pathogenic (Ara
) and nonpathogenic
(Ara+) biotypes reported in our study probably explains the
discrepancy between seroprevalence and disease prevalence in
melioidosis. People may be inoculated with the nonvirulent biotype
outside the disease-endemic area and produce antibodies against LPS.
These antibodies are considered the major component of the current
indirect hemagglutination assay for melioidosis. Altogether, it appears that the LPS of B. pseudomallei is both highly conserved and
constant. The detection of 4 clinical isolates with atypical LPS
patterns (among the 123 analyzed) is not unexpected, in view of the
fact that this has been previously noted by two other groups (11, 16). These earlier investigators presented structural studies indicating the possible presence of two different forms of LPS in
B. pseudomallei clinical isolates. The simultaneous
production of more than one structurally different form of LPS by a
gram-negative bacterium is known to occur. The unexpected observation
is that two of the four clinical isolates with atypical LPS patterns
were from patients experiencing a relapse of melioidosis. The relapsing status of the patients from whom the two remaining atypical isolates were taken could not be determined because one died after bacterial identification and the other had just recovered from the initial infection. The significance of this observation remains to be investigated.
The similarity of LPSs from Ara
(virulent) and
Ara+ (nonvirulent) B. pseudomallei isolates in
the present study was unexpected, since in general this immunodominant
component of gram-negative bacteria possesses different antigenic
carbohydrate side chains. The latter not only confer species
specificity but also determine virulence. This raises the question of
the role of LPS in the virulence and pathogenicity of B. pseudomallei. For many years, this area of investigation has given
inconsistent and controversial results (2, 6-9, 14, 17, 20,
24). Observations by Iwasa et al. (8) and more
recently by Matsuura et al. (14) suggested that the LPSs of
B. pseudomallei clinical isolates appeared to be less toxic
than those from other gram-negative bacteria. Our findings are
consistent with this conclusion, since we have shown here that the LPS
from the nonvirulent Ara+ isolates was indistinguishable
from that of its virulent Ara
counterpart. We have data
showing that unlike the situation with the LPSs, the antigenic
compositions of Ara+ and Ara
biotypes were
different from each other, based on their immunoreactivities with
polyclonal mouse and rabbit antisera and mouse monoclonal antibody
(unpublished data). Ho et al. recently demonstrated that anti-LPS
antibodies could mediate phagocytic killing of B. pseudomallei by polymorphonuclear leukocytes (7).
Additional investigation should give some insight that would be most
valuable in understanding the pathogenicity of B. pseudomallei and in development of a vaccine for melioidosis.
 |
ACKNOWLEDGMENTS |
This work was supported by the Chulabhorn Foundation, the
National Science and Technology Development Agency of Thailand, and the
Thailand Research Fund. V.W. and N.J.W. were supported by the
Wellcome-Mahidol University-Oxford Tropical Medicine Research Programme funded by the Wellcome Trust of Great Britain.
We are grateful to Surasakdi Wongratanacheewin (Department of
Microbiology, Faculty of Medicine, Khon Kaen University, Khon Kaen,
Thailand) for some of the clinical B. pseudomallei isolates used in this study.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology, Faculty of Science, Mahidol University, Rama 6 Rd.,
Bangkok 10400, Thailand. Phone: 662 246 2358, ext. 6606. Fax: 662 644 5411. E-mail: scssr{at}mahidol.ac.th.
 |
REFERENCES |
| 1.
|
Brett, P. J.,
D. Deshazer, and D. E. Woods.
1997.
Characterization of Burkholderia pseudomallei and Burkholderia pseudomallei-like strains.
Epidemiol. Infect.
118:137-148[Medline].
|
| 2.
|
Bryan, L. E.,
S. Wong,
D. E. Woods,
D. A. B. Dance, and W. Chaowagul.
1994.
Passive protection of diabetic rats with antisera specific for the polysaccharide portion of the lipopolysaccharide from Pseudomonas pseudomallei.
Can. J. Infect. Dis.
5:170-178.
|
| 3.
|
Chaowagul, W.,
N. J. White,
D. A. B. Dance,
Y. Wattanagoon,
P. Naigowit,
T. M. E. Davis,
S. Looareesuwan, and N. Pitakwatchara.
1989.
Melioidosis: a major course of community-acquired septicemia in northeastern Thailand.
J. Infect. Dis.
159:890-899[Medline].
|
| 4.
|
Dance, D. A. B.
1991.
Melioidosis: the tip of the iceberg?
Clin. Microbiol. Rev.
4:52-60[Abstract/Free Full Text].
|
| 5.
|
Fomsgaard, A.,
M. A. Freundenberg, and C. Galanos.
1990.
Modification of the silver staining technique to detect lipopolysaccharide in polyacrylamide gels.
J. Clin. Microbiol.
28:2627-2631[Abstract/Free Full Text].
|
| 6.
|
Gotoh, N.,
N. J. White,
W. Chaowagul, and D. E. Wood.
1994.
Isolation and characterization of the outer-membrane proteins of Burkholderia (Pseudomonas) pseudomallei.
Microbiology
140:797-805[Abstract].
|
| 7.
|
Ho, M.,
T. Schollaardt,
M. D. Smith,
M. B. Perry,
P. J. Brett,
W. Chaowagul, and L. E. Bryan.
1997.
Specificity and functional activity of anti-Burkholderia pseudomallei polysaccharide antibodies.
Infect. Immun.
65:3648-3653[Abstract].
|
| 8.
|
Iwasa, S.,
V. Petkanchanapong, and P. Naigowit.
1992.
Endotoxic property of Pseudomonas pseudomallei as detected by the body-weight decreasing reaction in mice. A comparison with P. cepacia and P. aeruginosa.
Jpn. J. Med. Sci. Biol.
45:33-47.
|
| 9.
|
Jayanetra, P.,
M. Vorachit, and J. W. Costerton.
1991.
Role of glycocalyx in melioidosis, p. 55-61.
In
Proceedings of the 5th European Congress of Clinical Microbiology and Infectious Diseases.
|
| 10.
|
Kawahara, K.,
S. Dejsirilert,
H. Danbara, and T. Ezaki.
1992.
Extraction and characterization of lipopolysaccharide from Pseudomonas pseudomallei.
FEMS Microbiol. Lett.
96:129-133.
|
| 11.
|
Knirel, Y. A.,
N. A. Paramonov,
A. S. Shashkov,
N. K. Kochetkov,
R. G. Yarullin,
S. M. Farber, and V. I. Efremenko.
1992.
Structure of the polysaccharide chains of Pseudomonas pseudomallei lipopolysaccharide.
Carbohydr. Res.
233:185-193[Medline].
|
| 12.
|
Laemmli, U. K.
1970.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature
227:680-685[Medline].
|
| 13.
|
Lowry, O. H.,
N. J. Rosebrough,
A. L. Farr, and R. J. Randall.
1951.
Protein measurement with the Folin phenol reagent.
J. Biol. Chem.
193:265-275[Free Full Text].
|
| 14.
|
Matsuura, M.,
K. Kawahara,
T. Ezaki, and M. Nakano.
1996.
Biological activities of lipopolysaccharide of Burkholderia (Pseudomonas) pseudomallei.
FEMS Microbiol. Lett.
137:79-83[Medline].
|
| 15.
|
Michael, A.,
J. Apicella,
M. Griffiss, and H. Schneider.
1994.
Isolation and characterization of lipopolysaccharides, lipooligosaccharides and lipid A.
Methods Enzymol.
235:242-252[Medline].
|
| 16.
|
Perry, M. B.,
L. L. Maclean,
T. Schollaardt,
L. E. Bryan, and M. Ho.
1995.
Structural characterization of the lipopolysaccharide O antigens of Burkholderia pseudomallei.
Infect. Immun.
63:3348-3352[Abstract].
|
| 17.
|
Phung, L. V.,
T. B. Tran,
H. Hotta,
E. Yabuuchi, and I. Yano.
1995.
Cellular lipid and fatty acid compositions of Burkholderia pseudomallei strains isolated from human and environment in Viet Nam.
Microbiol. Immunol.
39:105-116[Medline].
|
| 18.
|
Pitt, T. L.,
H. Aucken, and D. A. B. Dance.
1992.
Homogeneity of lipopolysaccharide antigens in Pseudomonas pseudomallei.
J. Infect.
25:139-146[Medline].
|
| 19.
|
Pyle, S. W., and W. B. Schill.
1985.
Rapid serological analysis of bacterial lipopolysaccharides by electrotransfer to nitrocellulose.
J. Immunol. Methods
85:371-382[Medline].
|
| 20.
|
Rapaport, F. T.,
J. W. Miller, and J. Ruch.
1961.
Endotoxic properties of Pseudomonas pseudomallei.
Arch. Pathol.
71:429-436.
|
| 21.
|
Rugdech, P.,
N. Anuntagool, and S. Sirisinha.
1995.
Monoclonal antibodies to Pseudomonas pseudomallei and their potential for diagnosis of melioidosis.
Am. J. Trop. Med. Hyg.
52:231-235.
|
| 22.
| Smith, M. D., B. J. Angus, V. Wuthiekanun, and
N. J. White. Arabinose assimilation defines a nonvirulent
biotype of Burkholderia pseudomallei. Infect. Immun.
65:4319-4321.
|
| 23.
|
Smith, M. D.,
V. Wuthiekanun,
A. L. Walsh, and N. J. White.
1995.
Quantitative recovery of Burkholderia pseudomallei from soil in Thailand.
Trans. R. Soc. Trop. Med. Hyg.
89:488-490[Medline].
|
| 24.
|
Velianov, D., and K. Naidenski.
1993.
Virulence and susceptibility to phagocytosis of Pseudomonas pseudomallei R- and S-forms for ground squirrels (Citellus citellus L.).
Acta Microbiol. Bulgarica
30:11-16.
|
| 25.
|
Weber, K., and M. Osborn.
1969.
The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis.
J. Biol. Chem.
244:4406-4412[Abstract/Free Full Text].
|
| 26.
|
White, C. A., and J. F. Kennedy.
1986.
Oligosaccharides, p. 37-54.
In
M. F. Chaplin, and J. F. Kennedy (ed.), Carbohydrate analysis: a practical approach. IRL Press, Oxford, United Kingdom.
|
| 27.
|
Wuthiekanun, V.,
M. D. Smith,
D. A. B. Dance,
A. L. Walsh,
T. L. Pitt, and N. J. White.
1996.
Biochemical characteristics of clinical and environmental isolates of Burkholderia pseudomallei.
J. Med. Microbiol.
45:408-412[Abstract].
|
| 28.
|
Yabuuchi, E., and M. Arakawa.
1993.
Burkholderia pseudomallei and melioidosis: be aware in temperate area.
Microbiol. Immunol.
37:823-836[Medline].
|
Clinical and Diagnostic Laboratory Immunology, March 1998, p. 225-229, Vol. 5, No. 2
1071-412X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Ekchariyawat, P., Pudla, S., Limposuwan, K., Arjcharoen, S., Sirisinha, S., Utaisincharoen, P.
(2005). Burkholderia pseudomallei-Induced Expression of Suppressor of Cytokine Signaling 3 and Cytokine-Inducible Src Homology 2-Containing Protein in Mouse Macrophages: a Possible Mechanism for Suppression of the Response to Gamma Interferon Stimulation. Infect. Immun.
73: 7332-7339
[Abstract]
[Full Text]
-
Tiyawisutsri, R., Peacock, S. J., Langa, S., Limmathurotsakul, D., Cheng, A. C., Chierakul, W., Chaowagul, W., Day, N. P. J., Wuthiekanun, V.
(2005). Antibodies from Patients with Melioidosis Recognize Burkholderia mallei but Not Burkholderia thailandensis Antigens in the Indirect Hemagglutination Assay. J. Clin. Microbiol.
43: 4872-4874
[Abstract]
[Full Text]
-
Cheng, A. C., Currie, B. J.
(2005). Melioidosis: Epidemiology, Pathophysiology, and Management. Clin. Microbiol. Rev.
18: 383-416
[Abstract]
[Full Text]
-
Nelson, M., Prior, J. L, Lever, M S., Jones, H. E, Atkins, T. P, Titball, R. W
(2004). Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis. J Med Microbiol
53: 1177-1182
[Abstract]
[Full Text]
-
Utaisincharoen, P., Anuntagool, N., Limposuwan, K., Chaisuriya, P., Sirisinha, S.
(2003). Involvement of Beta Interferon in Enhancing Inducible Nitric Oxide Synthase Production and Antimicrobial Activity of Burkholderiapseudomallei-Infected Macrophages. Infect. Immun.
71: 3053-3057
[Abstract]
[Full Text]
-
Atkins, T., Prior, R. G., Mack, K., Russell, P., Nelson, M., Oyston, P. C. F., Dougan, G., Titball, R. W.
(2002). A Mutant of Burkholderia pseudomallei, Auxotrophic in the Branched Chain Amino Acid Biosynthetic Pathway, Is Attenuated and Protective in a Murine Model of Melioidosis. Infect. Immun.
70: 5290-5294
[Abstract]
[Full Text]
-
ANUNTAGOOL, N., NAIGOWIT, P., PETKANCHANAPONG, V., ARAMSRI, P., PANICHAKUL, T., SIRISINHA, S.
(2000). Monoclonal antibody-based rapid identification of Burkholderia pseudomallei in blood culture fluid from patients with community-acquired septicaemia. J Med Microbiol
49: 1075-1078
[Abstract]
[Full Text]
-
Kespichayawattana, W., Rattanachetkul, S., Wanun, T., Utaisincharoen, P., Sirisinha, S.
(2000). Burkholderia pseudomallei Induces Cell Fusion and Actin-Associated Membrane Protrusion: a Possible Mechanism for Cell-to-Cell Spreading. Infect. Immun.
68: 5377-5384
[Abstract]
[Full Text]
-
Steinmetz, I., Reganzerowski, A., Brenneke, B., Häussler, S., Simpson, A., White, N. J.
(1999). Rapid Identification of Burkholderia pseudomallei by Latex Agglutination Based on an Exopolysaccharide-Specific Monoclonal Antibody. J. Clin. Microbiol.
37: 225-228
[Abstract]
[Full Text]